|
1
|
Klimczak A, Kempińska-Mirosławska B, Mik
M, Dziki L and Dziki A: Incidence of colorectal cancer in Poland in
1999–2008. Arch Med Sci. 7:673–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anderson JC and Shaw RD: Update on colon
cancer screening: Recent advances and observations in colorectal
cancer screening. Curr Gastroenterol Rep. 16:4032014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qi G, Kudo Y, Ando T, Tsunematsu T,
Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I and
Takata T: Nuclear Survivin expression is correlated with malignant
behaviors of head and neck cancer together with Aurora-B. Oral
Oncol. 46:263–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qi G, Ogawa I, Kudo Y, Miyauchi M,
Siriwardena BS, Shimamoto F, Tatsuka M and Takata T: Aurora-B
expression and its correlation with cell proliferation and
metastasis in oral cancer. Virchows Arch. 450:297–302. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qi G, Kudo Y, Tang B, Liu T, Jin S, Liu J,
Zuo X, Mi S, Shao W, Ma X, et al: PARP6 acts as a tumor suppressor
via downregulating Survivin expression in colorectal cancer.
Oncotarget. 7:18812–18824. 2016.PubMed/NCBI
|
|
7
|
Ikeguchi M, Ueta T, Yamane Y, Hirooka Y
and Kaibara N: Inducible nitric oxide synthase and survivin
messenger RNA expression in hepatocellular carcinoma. Clin Cancer
Res. 8:3131–3136. 2002.PubMed/NCBI
|
|
8
|
Wakana Y, Kasuya K, Katayanagi S, Tsuchida
A, Aoki T, Koyanagi Y, Ishii H and Ebihara Y: Effect of survivin on
cell proliferation and apoptosis in gastric cancer. Oncol Rep.
9:1213–1218. 2002.PubMed/NCBI
|
|
9
|
Sui L, Dong Y, Ohno M, Watanabe Y,
Sugimoto K and Tokuda M: Survivin expression and its correlation
with cell proliferation and prognosis in epithelial ovarian tumors.
Int J Oncol. 21:315–320. 2002.PubMed/NCBI
|
|
10
|
Qi G, Tuncel H, Aoki E, Tanaka S, Oka S,
Kaneko I, Okamoto M, Tatsuka M, Nakai S and Shimamoto F:
Intracellular localization of survivin determines biological
behavior in colorectal cancer. Oncol Rep. 22:557–562.
2009.PubMed/NCBI
|
|
11
|
Tuncel H, Shimamoto F, Qi H Kaneko
Guangying, Aoki E, Jikihara H, Nakai S, Takata T and Tatsuka M:
Nuclear Aurora B and cytoplasmic survivin expression is involved in
lymph node metastasis of colorectal cancer. Oncol Lett.
3:1109–1114. 2012.PubMed/NCBI
|
|
12
|
Tang B, Liang X, Tang F, Zhang J, Zeng S,
Jin S, Zhou L, Kudo Y and Qi G: Expression of USP22 and Survivin is
an indicator of malignant behavior in hepatocellular carcinoma. Int
J Oncol. 47:2208–2216. 2015.PubMed/NCBI
|
|
13
|
Andrianifahanana M, Moniaux N and Batra
SK: Regulation of mucin expression: Mechanistic aspects and
implications for cancer and inflammatory diseases. Biochim Biophys
Acta. 1765:189–222. 2006.PubMed/NCBI
|
|
14
|
Itoh Y, Kamata-Sakurai M, Denda-Nagai K,
Nagai S, Tsuiji M, Ishii-Schrade K, Okada K, Goto A, Fukayama M and
Irimura T: Identification and expression of human
epiglycanin/MUC21: A novel transmembrane mucin. Glycobiology.
18:74–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toribara NW, Gum JJ, Culhane PJ, Lagace
RE, Hicks JW, Petersen GM and Kim YS: MUC-2 human small intestinal
mucin gene structure. Repeated arrays and polymorphism. J Clin
Invest. 88:1005–1013. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Manne U, Weiss HL and Grizzle WE: Racial
differences in the prognostic usefulness of MUC1 and MUC2 in
colorectal adenocarcinomas. Clin Cancer Res. 6:4017–4025.
2000.PubMed/NCBI
|
|
17
|
Gurevich LE, Kazantseva IA, Korsakova NA,
Tsar'Kov PV and Polishchuk LO: Expression of type 1 and type 2
mucins in colonic epithelial tumors. Arkh Patol. 69:12–16. 2007.(In
Russian). PubMed/NCBI
|
|
18
|
Ishizu H, Kumagai J, Eishi Y, Takizawa T
and Koike M: Mucin core protein expression by colorectal mucinous
carcinomas with or without mucus hyperplasia. J Gastroenterol.
39:125–132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanoh A, Takeuchi H, Kato K, Waki M, Usami
K and Irimura T: Interleukin-4 induces specific pp-GalNAc-T
expression and alterations in mucin O-glycosylation in colonic
epithelial cells. Biochim Biophys Acta. 1780:577–584. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartman AE, Sanderson SJ, Ewing SL,
Niehans GA, Wiehr CL, Evans MK and Ho SB: Aberrant expression of
MUC5AC and MUC6 gastric mucin genes in colorectal polyps. Int J
Cancer. 80:210–218. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Imai Y, Yamagishi H, Fukuda K, Ono Y,
Inoue T and Ueda Y: Differential mucin phenotypes and their
significance in a variation of colorectal carcinoma. World J
Gastroenterol. 19:3957–3968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perrais M, Pigny P, Copin MC, Aubert JP
and Van Seuningen I: Induction of MUC2 and MUC5AC mucins by factors
of the epidermal growth factor (EGF) family is mediated by EGF
receptor/Ras/Raf/extracellular signal-regulated kinase cascade and
Sp1. J Biol Chem. 30:32258–32267. 2002. View Article : Google Scholar
|
|
23
|
Okamoto K, Okamoto I, Okamoto W, Tanaka K,
Takezawa K, Kuwata K, Yamaguchi H, Nishio K and Nakagawa K: Role of
Survivin in EGFR inhibitor-induced apoptosis in non-small cell lung
cancers positive for EGFR mutations. Cancer Res. 15:10402–10410.
2010. View Article : Google Scholar
|
|
24
|
Kang H, Min BS, Lee KY, Kim NK, Kim SN,
Choi J and Kim H: Loss of E-cadherin and MUC2 expressions
correlated with poor survival in patients with stages II and III
colorectal carcinoma. Ann Surg Oncol. 18:711–719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lugli A, Zlobec I, Baker K, Minoo P,
Tornillo L, Terracciano L and Jass JR: Prognostic significance of
mucins in colorectal cancer with different DNA mismatch-repair
status. J Clin Pathol. 60:534–539. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perçinel S, Savaş B, Ensari A, Kuzu I,
Kuzu MA, Bektaş M, Cetinkaya H and Kurşun N: Mucins in the
colorectal neoplastic spectrum with reference to conventional and
serrated adenomas. Turk J Gastroenterol. 18:230–238.
2007.PubMed/NCBI
|
|
27
|
Perez RO, Bresciani BH, Bresciani C,
Proscurshim I, Kiss D, Gama-Rodrigues J, Pereira DD, Rawet V,
Cecconnello I and Habr-Gama A: Mucinous colorectal adenocarcinoma:
Influence of mucin expression (Muc1, 2 and 5) on
clinico-pathological features and prognosis. Int J Colorectal Dis.
23:757–765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baas IO, Mulder JW, Offerhaus GJ,
Vogelstein B and Hamilton SR: An evaluation of six antibodies for
immunohistochemistry of mutant p53 gene product in archival
colorectal neoplasms. J Pathol. 172:5–12. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lanza G Jr, Maestri I, Dubini A, Gafa R,
Santini A, Ferretti S and Cavazzini L: p53 expression in colorectal
cancer: Relation to tumor type, DNA ploidy pattern and short-term
survival. Am J Clin Pathol. 105:604–612. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Biemer-Hüttmann AE, Walsh MD, McGuckin MA,
Ajioka Y, Watanabe H, Leggett BA and Jass JR: Immunohistochemical
staining patterns of MUC1, MUC2, MUC4, and MUC5AC mucins in
hyperplastic polyps, serrated adenomas, and traditional adenomas of
the colorectum. J Histochem Cytochem. 47:1039–1048. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Biemer-Huttmann AE, Walsh MD, McGuckin MA,
Simms LA, Young J, Leggett BA and Jass JR: Mucin core protein
expression in colorectal cancers with high levels of microsatellite
instability indicates a novel pathway of morphogenesis. Clin Cancer
Res. 6:1909–1916. 2000.PubMed/NCBI
|
|
32
|
Kocer B, Soran A, Erdogan S, Karabeyoglu
M, Yildirim O, Eroglu A, Bozkurt B and Cengiz O: Expression of
MUC5AC in colorectal carcinoma and relationship with prognosis.
Pathol Int. 52:470–477. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Losi L, Scarselli A, Benatti P, de Leon M
Ponz, Roncucci L, Pedroni M, Borghi F, Lamberti I, Rossi G, Marino
M, et al: Relationship between MUC5AC and altered expression of
MLH1 protein in mucinous and non-mucinous colorectal carcinomas.
Pathol Res Pract. 200:371–377. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aishima S, Kuroda Y, Nishihara Y, Taguchi
K, Taketomi A, Maehara Y and Tsuneyoshi M: Gastric mucin phenotype
defies tumour progression and prognosis of intrahepatic
cholangiocarcinoma: Gastric foveolar type is associated with
aggressive tumour behaviour. Histopathology. 49:35–44. 2006.
View Article : Google Scholar : PubMed/NCBI
|
